Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
Continuous clopidogrel therapy may lead to delayed and immediate bleeding after polypectomy, though only to a nonsignificant degree, reports a recent study.
The fully human monoclonal antibody secukinumab triumphed over ustekinumab once again in patients with moderate-to-severe plaque psoriasis, according to the phase IIIb CLARITY* trial presented at the recent annual meeting of the American Academy of Dermatology (AAD 2019).
Taking curcumin daily in addition to losing weight does not exert a superior effect on cardiovascular (CV) risk factors in patients with nonalcoholic fatty liver disease (NAFLD) when compared with losing weight alone, according to a study.
Adequate tea drinking (<240 ml/day or 19 cup-years) may help lower the risk of gallstones in both men and women, a recent Taiwan study has shown.
A Singapore study has shown that the muscle-sparing modification of the pedicled transverse rectus abdominis myocutaneous (MS-TRAM) flaps is on a par with conventional TRAM flap. The pedicled MS-TRAM preserves innervated muscle in the donor site, reducing time to ambulation and postoperative pain.
Lithium appears to be no better than placebo for maintaining the acute antidepressant response to ketamine in patients with treatment-resistant unipolar depression (TRD), a recent study has shown.
A smartwatch algorithm may help detect irregular heart rate – via a pulse notification – indicating possible atrial fibrillation (AF), according to preliminary results of the Apple Heart Study* presented at ACC.19.
Special Reports
At the Eisai-sponsored tea symposium during the 27th Malaysian Urological Conference at Shangri-La Kuala Lumpur, Professor Osamu Yokoyama highlighted the advantages of silodosin (Urief®, Eisai Inc.) in relieving lower urinary tract symptoms associated with benign prostate hyperplasia.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat osteoarthritis and rheumatoid arthritis to reduce joint pain and improve joint function. Dr Sazzli Kasim provides his viewpoint on how the current understanding on cardiovascular safety of NSAIDs should be taken into account when determining optimal analgesic strategies for patients with arthritis.
In March 2018, sublingual fentanyl citrate (SLF; Abstral®, Menarini) was made available in Malaysia. SLF is a rapid-onset opioid (ROO) indicated for the management of breakthrough cancer pain (BTcP) episodes in patients that are opioid-tolerant. In July 2018, Menarini organized an expert meeting, aptly named Malaysian Collaborative Meeting of Pain Specialists to Improve Oncology Management (MY-COMPASSION), comprising of key figures in anaesthesiology, palliative care and oncology to discuss current insights into local BTcP management. Below are highlights from the meeting.
Comprehensive genomic profiling (CGP) has emerged as a key driving force behind personalized cancer care. With the wealth of data available with CGP, medical oncologists now have in their armamentarium a tool that could enable them to provide patients with the optimum treatment. At a Roche Foundation Medicine-sponsored symposium held at the 2018 European Society of Medical Oncology (ESMO) Congress in Munich, Germany, a panel of experts reviewed key data on CGP, with a focus on the treatment of advanced cancers.
In an era of antimicrobial resistance, newer agents are urgently needed. Ceftaroline, a broad spectrum cephalosporin approved for the treatment of community-acquired pneumonia (CAP) and complicated skin and soft tissue infections (cSSTI) is a step forward towards addressing this need. MIMS Anti-Infectives interviewed Dr Asok Kurup, an infectious disease physician practising at the Mount Elizabeth Medical Centre in Singapore, to provide some insights into the role of ceftaroline for the treatment of these conditions.
In conjunction with the launch of QV Intensive with Ceramides (Ego Pharm), the important role of ceramides in themanagement of atopic dermatitis (AD) was highlighted by two distinguished speakers, Dr Agnes Heng of KPJ and Pantai Hospital Ipoh, as well as Dr Fabrizio Spada of Ego Pharmaceuticals, Australia.
At the recent 34th Annual Congress of the Malaysian Society of Nephrology, Dr Kyriaki Stamatelou reviewed the role of alfacalcidol (One-Alpha®; LEO Pharma) – a vitamin D analogue – in the prevention and management of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD).
Conference Reports
The fully human monoclonal antibody secukinumab triumphed over ustekinumab once again in patients with moderate-to-severe plaque psoriasis, according to the phase IIIb CLARITY* trial presented at the recent annual meeting of the American Academy of Dermatology (AAD 2019).
A smartwatch algorithm may help detect irregular heart rate – via a pulse notification – indicating possible atrial fibrillation (AF), according to preliminary results of the Apple Heart Study* presented at ACC.19.
The humanized immunoglobulin G1 monoclonal antibody risankizumab provided durable clinical efficacy compared with ustekinumab in individuals with moderate-to-severe plaque psoriasis, according to integrated analyses of UltIMMa-1 and 2* presented at AAD 2019.
Long-term use of the humanized immunoglobulin G1K monoclonal antibody tildrakizumab generated durable responses in adult patients with moderate-to-severe chronic plaque psoriasis*, according to the results of the 3-year extension phases of reSURFACE 1** and 2*** presented at AAD 2019.
The novel Janus kinase (JAK) inhibitor delgocitinib exhibited favourable efficacy and safety for moderate-to-severe atopic dermatitis (AD), according to a phase III study presented at AAD 2019.
Patients with renal cell carcinoma (RCC) who received the first-line combination of avelumab and axitinib had longer progression-free survival (PFS) compared with those who received sunitinib, particularly those with PD-L1–positive tumours, according to findings of the phase III JAVELIN Renal 101* trial.
Adjuvant chemotherapy using S-1 plus oxaliplatin (SOX) or tegafur-uracil/leucovorin (UFT/LV) led to similar disease-free survival (DFS) rates in patients with high-risk stage III colon cancer, according to updated results of the ACTS-CC 02* presented at ASCO GI 2019.
Multimedia
